Literature DB >> 12590708

Influence of ex vivo expansion and retrovirus-mediated gene transfer on primary T lymphocyte phenotype and functions.

Delphine Sauce1, Nicolas Tonnelier, Anne Duperrier, Bruno Petracca, Marcelo de Carvalho Bittencourt, Mounir Saadi, Philippe Saas, Christophe Ferrand, Patrick Herve, Pierre Tiberghien, Eric Robinet.   

Abstract

To modulate alloreactivity after hematopoietic stem cell (HSC) transplantation, suicide gene-expressing donor T cells can be administered with an allogeneic T cell-depleted HSC graft. Immune competence of such cells is a critical issue. We have examined the impact of our ex vivo gene transfer protocol (12-day culture period including CD3/IL-2 activation, retrovirus-mediated gene transfer, and G418-based selection) on the phenotype and functional properties of gene-modified cells (GMC). GMC were compared with control cells that had been cultured in parallel with GMC, but nontransduced and nonselected, as well as with peripheral blood mononuclear cells (PBMC). Our data show that phenotypical modifications are similar in control cells and GMC, demonstrating that alterations result from the 12-day culture rather than from the transduction and/or selection process itself. Such modifications include a reversal of CD4/CD8 ratio, activated phenotype (increased expression of CD45RO, CD95, and HLA-DR), and acquisition or increased expression of co-stimulatory molecules (CD80, CD86, and CD40). This led to an enhanced allostimulating potential of GMC, as compared with resting T cells, when used as stimulating cells in mixed lymphocyte reactions. Conversely, when using them as responder cells in mixed lymphocyte reactions, GMC exhibited a rapid loss of alloreactivity that resulted both from culture-dependent and from transduction and/or selection-dependent events. In conclusion, the retrovirus-mediated gene transfer can be associated with major phenotypical and functional alterations that could have strong clinical implications (increased immunogenicity, reduced anti-leukemic effect). Thus, future T cell expansion protocols should try to improve not only cell expansion or gene transfer efficiency, but also T cell functions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12590708     DOI: 10.1089/152581602321080592

Source DB:  PubMed          Journal:  J Hematother Stem Cell Res        ISSN: 1525-8165


  10 in total

1.  Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept.

Authors:  C Leboeuf; J Roser-Schilder; M Lambotin; S Durand; T Wu; C Fauvelle; B Su; E Bôle-Richard; M Deschamps; C Ferrand; P Tiberghien; P Pessaux; T F Baumert; E Robinet
Journal:  Gene Ther       Date:  2014-11-13       Impact factor: 5.250

2.  Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation.

Authors:  Sylvia Borchers; Elena Provasi; Anna Silvani; Marina Radrizzani; Claudia Benati; Elke Dammann; Annika Krons; Julia Kontsendorn; Joerg Schmidtke; Wolfgang Kuehnau; Nils von Neuhoff; Michael Stadler; Fabio Ciceri; Chiara Bonini; Arnold Ganser; Bernd Hertenstein; Eva M Weissinger
Journal:  Hum Gene Ther       Date:  2011-03-30       Impact factor: 5.695

3.  In vivo proof of concept of adoptive immunotherapy for hepatocellular carcinoma using allogeneic suicide gene-modified killer cells.

Authors:  Céline Leboeuf; Laurent Mailly; Tao Wu; Gaetan Bour; Sarah Durand; Nicolas Brignon; Christophe Ferrand; Christophe Borg; Pierre Tiberghien; Robert Thimme; Patrick Pessaux; Jacques Marescaux; Thomas F Baumert; Eric Robinet
Journal:  Mol Ther       Date:  2013-12-06       Impact factor: 11.454

Review 4.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

5.  Regulatory T-cell expansion and function do not account for the impaired alloreactivity of ex vivo-expanded T cells.

Authors:  Nicolas Montcuquet; Patricia Mercier-Letondal; Sylvain Perruche; Anne Duperrier; Mélanie Couturier; Abdelghani Bouchekioua; Mark Bonyhadi; Christophe Ferrand; Pierre Tiberghien; Eric Robinet
Journal:  Immunology       Date:  2008-04-26       Impact factor: 7.397

6.  Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.

Authors:  S Yang; C J Cohen; P D Peng; Y Zhao; L Cassard; Z Yu; Z Zheng; S Jones; N P Restifo; S A Rosenberg; R A Morgan
Journal:  Gene Ther       Date:  2008-05-22       Impact factor: 5.250

7.  Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells.

Authors:  Shicheng Yang; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunother       Date:  2008 Nov-Dec       Impact factor: 4.456

8.  Exposure to hypomethylating agent, 5-azacytidine, may improve iCasp9 suicide gene therapy for treating GvHD in allografts.

Authors:  E Bôle-Richard; C Gamonet; J-M Certoux; I Idirene; F Larosa; E Deconinck; A-M Mosseley; P Tiberghien; C Borg; C Ferrand; M Deschamps
Journal:  Gene Ther       Date:  2016-05-12       Impact factor: 5.250

Review 9.  Genetically engineered T cells for the treatment of cancer.

Authors:  M Essand; A S I Loskog
Journal:  J Intern Med       Date:  2013-02       Impact factor: 8.989

10.  Quantifying biomass changes of single CD8+ T cells during antigen specific cytotoxicity.

Authors:  Thomas A Zangle; Daina Burnes; Colleen Mathis; Owen N Witte; Michael A Teitell
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.